748 Phase 1/2 study of the hexavalent OX40 agonist INBRX-106 alone and in combination with pembrolizumab in select solid tumors

Registros relacionados

• 1360 Treatment with a novel hexavalent OX40 agonist remodels the tumor microenvironment to favor anti-tumor immunity in mice
  por: William L Redmond, et al.
  Publicado em: (2023-11-01)
• 748 Phase 1/2 study of the hexavalent OX40 agonist INBRX-106 alone and in combination with pembrolizumab in select solid tumors
  por: Daniel Olson, et al.
  Publicado em: (2023-11-01)
• INBRX-120, a CD8α-targeted detuned IL-2 that selectively expands and activates tumoricidal effector cells for safe and durable in vivo responses
  por: Jason Ho, et al.
  Publicado em: (2023-01-01)
• Bacterial colonization of tumors drives immune activation and checkpoint blockade efficacy
  por: Annah S. Rolig, et al.
  Publicado em: (2026-02-01)
• 742 Phase 1/2 study of the bispecific 4–1BB and PD-L1 antibody INBRX-105 alone and in combination with pembrolizumab in select solid tumors
  por: David Hong, et al.
  Publicado em: (2023-11-01)